Showing 2371-2380 of 7016 results for "".
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
https://reachmd.com/programs/cme/inside-the-4-hits-targeting-april-to-change-the-course-of-igan/48815/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
https://reachmd.com/programs/project-oncology/establishing-d-vrd-efficacy-for-transplant-ineligible-multiple-myeloma/30049/Read about the effectiveness of adding daratumumab to the standard VRd regimen for patients with newly diagnosed multiple myeloma.The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
https://reachmd.com/programs/cme/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.IgAN SOC: Strengths and Limits
https://reachmd.com/programs/cme/igan-soc-strengths-and-limits/54682/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Mechanism-Based Targeting: Why APRIL Matters in IgAN
https://reachmd.com/programs/cme/mechanism-based-targeting-why-april-matters-in-igan/54681/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.APRIL Uncovered: An Upstream Driver in IgAN
https://reachmd.com/programs/cme/april-uncovered-an-upstream-driver-in-igan/54680/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Sjögren’s Disease Management: A Decade in Review
https://reachmd.com/programs/living-rheum/sjogrens-disease-management-a-decade-in-review/36342/Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
https://reachmd.com/programs/cme/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Chimeric Antigen Receptor T-Cell Therapy for Progressive Multiple Sclerosis: Rationale, Evidence, and Therapeutic Potential
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/chimeric-antigen-receptor-t-cell-therapy-for-progressive-multiple-sclerosis-rationale-evidence-and-therapeutic-potential/56914/CAR T-cell therapy represents a new strategy for treating progressive multiple sclerosis by targeting pathogenic B cells involved in compartmentalized neuroinflammation.